RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
RedHill Biopharma (RDHL) Tops Q2 EPS by 6c, Revenue Misses Consensus
August 26, 2021 7:10 AM EDTRedHill Biopharma (NASDAQ: RDHL) reported Q2 EPS of ($0.06), $0.06 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $21.5 million versus the consensus estimate of $25.02 million.
For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.
... More


